Clexio Biosciences

In the search for new models to enhance precision in drug development in Psychiatry, Clexio Biosciences is proud to have collaborated with NeuroKaire (formerly Genetika+) to explore the utility of NeuroKaire’s biomarker for profiling the efficacy of antidepressant compounds. The findings were presented in a poster at the #CNSSummit.   This approach was used to assess CLE-100's (parent and metabolite) effect on synaptic plasticity in iPSC-derived neurons, from individual well-characterized depressed patients.   CLE-100 is an investigational drug and is currently not approved for commercial distribution. For a look at the full poster, click: https://lnkd.in/dabt-tqe   For more information on Clexio please visit our website: www.clexio.com   #depression #MDD #CLE-100 #esketamine #CNSSummit 

We are pleased to share that we have reached 50% enrollment in the SOLEO study, a Phase 2 study assessing the safety and efficacy of CLE-100 as an adjunctive treatment in subjects with Major Depressive Disorder, who have had inadequate response to standard antidepressant therapies. The study is enrolling in the US. CLE-100 is an investigational drug and is currently not approved for commercial distribution. For more information on SOLEO, please visit: https://lnkd.in/daJA-qyC To learn more about CLE-100, visit  https://lnkd.in/d5RXyPt   #ClinicalTrials #MDD #Clexio #CNS #psychiatry #mentalhealth

We are happy to share that Dr. Orna Goren will be presenting CLE-400 at the 33rd European Academy of Dermatology and Venereology (EADV) congress in Amsterdam on September 26th. CLE-400 is a topical α2-adrenergic agonist being developed as a novel mechanism for treating chronic pruritus associated with notalgia paresthetica. The program is currently in Phase 2. 26 September, 11:15 CEST  (G104-G105) For more information on CLE-400 and the rest of Clexio’s pipeline:  https://lnkd.in/d5RXyPt #EADVCongress #Notalgiaparesthetica #dermatology #pruritus #itch #clexio  

We are excited to share that Hadile Ounallah-Saad, Clexio's Head of Innovation- Early Stage Pipeline, will be presenting CLE-905 at the 7th Neuropsychiatric Drug Development Summit in Boston, on September 25th.    CLE-905 is a potent dual M1/M4 receptor agonist in development for the treatment of Schizophrenia and other Psychiatric Conditions. Come join us on 25 September, at 3.50pm EST   For more information on CLE-905 and the rest of Clexio’s pipeline: https://lnkd.in/d5RXyPt   #drugdevelopment #schitzophrenia #Clexio #innovation 

Clexio Biosciences is pleased to announce that we have reached 50% enrollment in our CLE-400 Phase 2 proof-of-concept study, in subjects suffering from chronic pruritus associated with Notalgia Paresthetica.   The study is a randomized, double-blind, vehicle-controlled multi-center study, enrolling in the US, assessing the efficacy and safety of our CLE-400 topical gel.   Notalgia Paresthetica is a type of sensory neuropathy associated with chronic itch in the upper back. Patients’ quality of life, sleep, and mood can be negatively impacted by this condition. To-date, there are no approved treatments for this condition.   CLE-400 is a topical formulation containing a potent α2-adrenergic agonist, a non-opioid and non-steroid. CLE-400 is an investigational drug and is currently not approved for commercial distribution. For more information on CLE-400: https://lnkd.in/dQ-GJkwE #clexio #clinicaltrials #notalgiaparesthetica #itch #dermatology #neuropathy